These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11438833)

  • 21. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
    Tao J; Tu YT; Huang CZ; Feng AP; Wu Q; Lian YJ; Zhang LX; Zhang XP; Shen GX
    Br J Dermatol; 2005 Oct; 153(4):715-24. PubMed ID: 16181451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
    Barzon L; Gnatta E; Castagliuolo I; Trevisan M; Moretti F; Pontecorvi A; Boscaro M; Palù G
    Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory mechanisms controlling human hepatocyte nuclear factor 4alpha gene expression.
    Hatzis P; Talianidis I
    Mol Cell Biol; 2001 Nov; 21(21):7320-30. PubMed ID: 11585914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-gamma regulation of the human mimecan promoter.
    Tasheva ES; Conrad GW
    Mol Vis; 2003 Jun; 9():277-87. PubMed ID: 12835654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The UV responsive elements in the human mimecan promoter: a functional characterization.
    Tasheva ES; Conrad GW
    Mol Vis; 2003 Jan; 9():1-9. PubMed ID: 12533723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
    Inoue T; Maeno A; Talbot C; Zeng Y; Yeater DB; Leman ES; Kulkarni P; Ogawa O; Getzenberg RH
    Prostate; 2009 Jun; 69(8):861-73. PubMed ID: 19267365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.
    Hurtado Picó A; Wang X; Sipo I; Siemetzki U; Eberle J; Poller W; Fechner H
    Mol Ther; 2005 Apr; 11(4):563-77. PubMed ID: 15771959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
    Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
    Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
    Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
    Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
    Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo.
    Mavria G; Jäger U; Porter CD
    Gene Ther; 2000 Mar; 7(5):368-76. PubMed ID: 10694818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells.
    Lefort K; Rouault JP; Tondereau L; Magaud JP; Doré JF
    Oncogene; 2001 Nov; 20(50):7375-85. PubMed ID: 11704867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A stress regulatory network for co-ordinated activation of proteasome expression mediated by yeast heat shock transcription factor.
    Hahn JS; Neef DW; Thiele DJ
    Mol Microbiol; 2006 Apr; 60(1):240-51. PubMed ID: 16556235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of PLZF in melanoma progression.
    Felicetti F; Bottero L; Felli N; Mattia G; Labbaye C; Alvino E; Peschle C; Colombo MP; Carè A
    Oncogene; 2004 Jun; 23(26):4567-76. PubMed ID: 15077196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters.
    Nettelbeck DM; Jérôme V; Müller R
    Gene Ther; 1998 Dec; 5(12):1656-64. PubMed ID: 10023445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression.
    Smith-Arica JR; Morelli AE; Larregina AT; Smith J; Lowenstein PR; Castro MG
    Mol Ther; 2000 Dec; 2(6):579-87. PubMed ID: 11124058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cellular oncogene EWS/activating transcription factor 1 is unable to activate adenovirus-borne promoters: implications for cytotoxic prodrug therapy of malignant melanoma of soft parts.
    Lung RW; Lee KA
    Cancer Gene Ther; 2000 Mar; 7(3):396-406. PubMed ID: 10766345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers.
    Modlich U; Pugh CW; Bicknell R
    Gene Ther; 2000 May; 7(10):896-902. PubMed ID: 10845728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.